Rubraca Conditionally Rejected for Use on NHS England for Recurrent Ovarian Cancer
News
Rubraca (rucaparib), a therapy for relapsed or progressive ovarian, fallopian, or primary peritoneal cancer, was provisionally rejected for use on England’s National Health Service (NHS). In justifying its decision, the ... Read more